Figure 3.

Dynamic changes of regulatory CD4⁺ T cells in MG patients and their QMG scores during IVIg therapy demonstrated a positive correlation between IVIg therapeutic effect and frequency of Tregs and CTLA-4⁺ Tregs. The individual (a) and mean (b) QMG scores were determined for MG patients (n = 20) during the two courses of IVIg therapy. The individual and mean frequency of CD4⁺CD25⁺FOXP3⁺ Treg cells (c, d) and CD4⁺CD25⁺FOXP3⁺CTLA-4⁺ Treg cells (e, f) were measured by FACS analysis of PBMCs from IVIg-treated MG patients (n = 20).